In a phase I clinical trial, Rova-T was more effective in SCLC with DLL3 overexpression (defined as expression in at least 50% of cancer cells by immunohistochemistry) compared with SCLC with a low level of DLL3 expression (5). This evidence concerns the gene DLL3 and small cell lung carcinoma.